Ensuring access to HPV vaccines through integrated services: a reproductive health perspective.

In 2006, a quadrivalent human papillomavirus (HPV) vaccine was licensed, and another vaccine may be licensed soon. Little is known about the practical considerations involved in designing and implementing cervical cancer prevention programmes that include vaccination as a primary means of prevention. Although the vaccine may ultimately be indicated for both males and females, young girls, or girls and women aged 9-25 years, will be the initial candidates for the vaccine.

Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial.

Context: Non-cytology-based screen-and-treat approaches for cervical cancer prevention have been developed for low-resource settings, but few have directly addressed efficacy.

Objective: To determine the safety and efficacy of 2 screen-and-treat approaches for cervical cancer prevention that were designed to be more resource-appropriate than conventional cytology-based screening programs.

Design, Setting, And Patients: Randomized clinical trial of 6555 nonpregnant women, aged 35 to 65 years, recruited through community outreach and conducted between June 2000 and December 2002 at ambulatory women's health clinics in Khayelitsha, South Africa.

A prospective study of time and number of ejaculations to azoospermia after vasectomy by ligation and excision.

Purpose: We obtained detailed information on the time and number of ejaculations to azoospermia after vasectomy by ligation and excision.

Materials And Methods: Men seeking vasectomy at 3 public clinics in Mexico City were invited to participate in this prospective noncomparative study. Vasectomy was performed using the no-scalpel technique.